Clinical Trials Logo

Endometrial Hyperplasia clinical trials

View clinical trials related to Endometrial Hyperplasia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06390904 Recruiting - Obesity Clinical Trials

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.

NCT ID: NCT06379113 Recruiting - Obesity Clinical Trials

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.

NCT ID: NCT06102863 Recruiting - Clinical trials for Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I

Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

NCT ID: NCT05697601 Recruiting - Ovarian Cancer Clinical Trials

Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools

Start date: February 28, 2023
Phase:
Study type: Observational

The goal of this observational study is to explore the possible associated factors of ovarian cancer and endometrial cancer in Indonesia and develop screening tools that could predict the risk of both types of cancer The specific objectives of the study are 1. Elaborating the situation of ovarian and endometrial cancer in Indonesia 2. Exploring the possible clinical, demography and laboratory predictors of these diseases 3. Develop artificial-intelligence-based screening tools for both type of cancer based on possible predictors This study will utilize the patient registry diagnosed with ovarian and endometrial cancer. We assumed that several demography, clinical, and laboratory predictors might possess good screening performance with higher sensitivity and specificity (>80%).

NCT ID: NCT05675787 Recruiting - Clinical trials for Atypical Endometrial Hyperplasia

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Start date: January 6, 2023
Phase: Phase 2
Study type: Interventional

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

NCT ID: NCT05647109 Recruiting - Clinical trials for Atypical Endometrial Hyperplasia

Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation

NCT ID: NCT05492487 Recruiting - Fertility Issues Clinical Trials

A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore

Start date: January 3, 2020
Phase: Phase 2
Study type: Interventional

The investigators' objective is to determine the regression rate, side effects and acceptability of Mirena compared to megace in the treatment of atypical endometrial hyperplasia among women desiring fertility.

NCT ID: NCT05316935 Recruiting - Clinical trials for Endometrial Neoplasms

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

NCT ID: NCT05316493 Recruiting - Clinical trials for Overweight and Obesity

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Start date: June 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

NCT ID: NCT05292573 Recruiting - Female Clinical Trials

Longitudinal Follow-up in Women With Endometrial Hyperplasia Without Atypia

Start date: August 1, 2018
Phase: Phase 3
Study type: Interventional

This study will prospectively enroll a total of 1000 patients (200 per year) simple hyperplasia/complex hyperplasia (SH/CH) without atypia. All subjects will receive education for exercise and weight control and be randomized 1:1 to with or without metformin intervention. At the end of this 3-year project, an interim analysis will be performed. Since long-term follow-up is intended, therefore for the 4th to 6th year a new grant support will be looked for. The long-term occurrence of endometrial cancer (up to15 years) data will be acquired from national cancer registry, which permission is addressed in the informed sent.